0353 GMT - Australia-listed drug and device makers may have to consider moving production due to potential tariffs by the incoming Trump administration, UBS analysts write in a note. They say that the likes of vaccine giant CSL, hearing-implant maker Cochlear, breath-tech provider ResMed and radiopharmaceutical developer Telix may have to consider the origin of various inputs and the location of production. Tariffs could motivate relocation of facilities to the U.S. but result in lower profitability for companies, they say. Protective-garment maker Ansell could benefit from tariffs on Chinese gloves, they add. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 06, 2024 22:53 ET (03:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。